Novartis Collaborates with Precision Bio in Gene Editing Pact
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 6 (Table of Contents)
Published: 24 Jun-2022
DOI: 10.3833/pdr.v2022.i6.2699 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Novartis has entered into an in vivo gene editing collaboration and licensing agreement with Precision Biosciences to develop potentially curative therapies for certain haemoglobinopathies such as sickle cell disease and beta thalassemia...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS